Cargando…

Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis

BACKGROUND: Non‐adherence is a significant problem in bipolar disorder. Second‐generation antipsychotics (SGA) long‐acting injections (LAIs) may improve adherence in bipolar disorder and may prevent relapses. However, the evidence is limited and conflicting. OBJECTIVE: The objective of this study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Prajapati, Asta R., Wilson, Jon, Song, Fujian, Maidment, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587954/
https://www.ncbi.nlm.nih.gov/pubmed/30417552
http://dx.doi.org/10.1111/bdi.12707
_version_ 1783429174350839808
author Prajapati, Asta R.
Wilson, Jon
Song, Fujian
Maidment, Ian
author_facet Prajapati, Asta R.
Wilson, Jon
Song, Fujian
Maidment, Ian
author_sort Prajapati, Asta R.
collection PubMed
description BACKGROUND: Non‐adherence is a significant problem in bipolar disorder. Second‐generation antipsychotics (SGA) long‐acting injections (LAIs) may improve adherence in bipolar disorder and may prevent relapses. However, the evidence is limited and conflicting. OBJECTIVE: The objective of this study was to evaluate efficacy and safety of SGA LAIs in bipolar disorder. METHOD: Systematic review and meta‐analysis of randomised controlled trials (RCTs) (≥6 months duration) investigating safety and efficacy of SGA LAIs for bipolar disorder. We searched Pubmed, Embase, CINAHL, Cochrane, PsycINFO, LiLACS, www.clinicaltrials.gov up to October 2016. We also contacted the manufacturers of SGA LAIs. Primary efficacy and safety outcomes were relapse rate and all‐cause discontinuation respectively. RESULTS: Total of seven RCTs (n = 1192) were included. SGA LAIs show superiority over placebo for study‐defined relapse rate (RR = 0.58, 95% CI = 0.49‐0.68, P < 0.00001) and all‐cause discontinuation (RR = 0.72, 95% CI = 0.64‐0.82, P < 0.00001). However, no significant difference was found between SGA LAIs and oral active control for relapse rate (RR = 0.92, P = 0.79) and all‐cause discontinuation (RR = 1.2, P = 0.31). In terms of secondary outcomes, SGA LAIs performed better than placebo in relapse to mania/hypomania, young mania rating scales (YMRS), clinical global impression‐severity (CGI‐S), montgomery‐asberg depression rating scale (MADRS). There was no significant difference between SGA LAIs and oral active control regarding relapse to mania/hypomania, YMRS, CGI‐S, extra‐pyramidal side effects (EPSEs), weight gain. However, the active control performed better than SGA LAIs in relapse to depression, MADRS, and prolactin‐related AEs. CONCLUSIONS: Current evidence is very limited to support the use of SGA LAIs (compared to oral medication) in bipolar disorder. Further high‐quality studies, particularly comparing SGA LAIs with active control, are warranted.
format Online
Article
Text
id pubmed-6587954
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65879542019-07-02 Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis Prajapati, Asta R. Wilson, Jon Song, Fujian Maidment, Ian Bipolar Disord Research Articles BACKGROUND: Non‐adherence is a significant problem in bipolar disorder. Second‐generation antipsychotics (SGA) long‐acting injections (LAIs) may improve adherence in bipolar disorder and may prevent relapses. However, the evidence is limited and conflicting. OBJECTIVE: The objective of this study was to evaluate efficacy and safety of SGA LAIs in bipolar disorder. METHOD: Systematic review and meta‐analysis of randomised controlled trials (RCTs) (≥6 months duration) investigating safety and efficacy of SGA LAIs for bipolar disorder. We searched Pubmed, Embase, CINAHL, Cochrane, PsycINFO, LiLACS, www.clinicaltrials.gov up to October 2016. We also contacted the manufacturers of SGA LAIs. Primary efficacy and safety outcomes were relapse rate and all‐cause discontinuation respectively. RESULTS: Total of seven RCTs (n = 1192) were included. SGA LAIs show superiority over placebo for study‐defined relapse rate (RR = 0.58, 95% CI = 0.49‐0.68, P < 0.00001) and all‐cause discontinuation (RR = 0.72, 95% CI = 0.64‐0.82, P < 0.00001). However, no significant difference was found between SGA LAIs and oral active control for relapse rate (RR = 0.92, P = 0.79) and all‐cause discontinuation (RR = 1.2, P = 0.31). In terms of secondary outcomes, SGA LAIs performed better than placebo in relapse to mania/hypomania, young mania rating scales (YMRS), clinical global impression‐severity (CGI‐S), montgomery‐asberg depression rating scale (MADRS). There was no significant difference between SGA LAIs and oral active control regarding relapse to mania/hypomania, YMRS, CGI‐S, extra‐pyramidal side effects (EPSEs), weight gain. However, the active control performed better than SGA LAIs in relapse to depression, MADRS, and prolactin‐related AEs. CONCLUSIONS: Current evidence is very limited to support the use of SGA LAIs (compared to oral medication) in bipolar disorder. Further high‐quality studies, particularly comparing SGA LAIs with active control, are warranted. John Wiley and Sons Inc. 2018-11-11 2018-12 /pmc/articles/PMC6587954/ /pubmed/30417552 http://dx.doi.org/10.1111/bdi.12707 Text en © 2018 The Authors. Bipolar Disorders Published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Prajapati, Asta R.
Wilson, Jon
Song, Fujian
Maidment, Ian
Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis
title Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis
title_full Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis
title_fullStr Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis
title_full_unstemmed Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis
title_short Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis
title_sort second‐generation antipsychotic long‐acting injections in bipolar disorder: systematic review and meta‐analysis
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587954/
https://www.ncbi.nlm.nih.gov/pubmed/30417552
http://dx.doi.org/10.1111/bdi.12707
work_keys_str_mv AT prajapatiastar secondgenerationantipsychoticlongactinginjectionsinbipolardisordersystematicreviewandmetaanalysis
AT wilsonjon secondgenerationantipsychoticlongactinginjectionsinbipolardisordersystematicreviewandmetaanalysis
AT songfujian secondgenerationantipsychoticlongactinginjectionsinbipolardisordersystematicreviewandmetaanalysis
AT maidmentian secondgenerationantipsychoticlongactinginjectionsinbipolardisordersystematicreviewandmetaanalysis